AEON Biopharma
Yahoo Finance • 5 days ago
AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update
– Multiple near-term potential milestones, including anticipated completion of primary structure analysis and select functional analyses in 3Q’25 – – Type 2a meeting with the FDA anticipated in 4Q’25– – Cash runway expected to support op... Full story
Yahoo Finance • 3 months ago
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
IRVINE, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therap... Full story
Yahoo Finance • 3 months ago
AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025
IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therap... Full story
Yahoo Finance • 4 months ago
AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer
IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple ther... Full story
Yahoo Finance • 5 months ago
AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
– Initiated analytical studies in Q4 2024to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025– – Pursuing a 351(k) regulatory pathway for ABP-450, which offer... Full story
Yahoo Finance • 5 months ago
AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference
IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today ann... Full story
Yahoo Finance • 6 months ago
AEON Biopharma, Inc. Announces Reverse Stock Split
IRVINE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today anno... Full story
Yahoo Finance • 6 months ago
AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
IRVINE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today anno... Full story
